{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:18:03Z","timestamp":1792513083389,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004571","name":"Minist\u00e8re des Affaires Sociales et de la Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004571","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jval.2020.11.010","type":"journal-article","created":{"date-parts":[[2021,3,7]],"date-time":"2021-03-07T06:51:22Z","timestamp":1615099882000},"page":"683-690","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response"],"prefix":"10.1016","volume":"24","author":[{"given":"Cyril","family":"Astrugue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"B\u00e9nard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Bosco-Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Dulucq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Rouyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis","family":"Lassalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jval.2020.11.010_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.respe.2015.12.017","article-title":"Cancer incidence in France over the 1980-2012 period: hematological malignancies","volume":"64","author":"Le Guyader-Peyrou","year":"2016","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.1016\/j.jval.2020.11.010_bib2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.leukres.2018.04.008","article-title":"The rising prevalence of chronic myeloid leukemia in France","volume":"69","author":"Delord","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.jval.2020.11.010_bib3","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1002\/cncr.26679","article-title":"Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy","volume":"118","author":"Huang","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2020.11.010_bib4","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population","volume":"34","author":"Bower","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2020.11.010_bib5","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jval.2020.11.010_bib6","author":"Le Guyader-Peyrou"},{"key":"10.1016\/j.jval.2020.11.010_bib7","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1016\/j.respe.2016.03.096","article-title":"Evaluation of the cost of chronic myeloid leukaemia management in the Midi-Pyr\u00e9n\u00e9es","volume":"64","author":"Mouni\u00e9","year":"2016","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.1016\/j.jval.2020.11.010_bib8","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/leu.2016.115","article-title":"The concept of treatment-free remission in chronic myeloid leukemia","volume":"30","author":"Sau\u00dfele","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jval.2020.11.010_bib9","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2020.11.010_bib10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jval.2020.11.010_bib11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.jval.2020.11.010_bib12","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.jval.2020.11.010_bib13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1111\/bjh.16408","article-title":"Risk of molecular recurrence after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: a systematic review of literature with a meta-analysis of studies over the last 10 years","volume":"189","author":"Dulucq","year":"2020","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.jval.2020.11.010_bib14","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/10428194.2015.1049166","article-title":"Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients","volume":"57","author":"Park","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jval.2020.11.010_bib15","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/blood.V128.22.1891.1891","article-title":"Patient-reported quality of life before and after stopping treatment in the ENESTop trial of treatment-free remission for patients with chronic myeloid leukemia in chronic phase","volume":"128","author":"Mahon","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jval.2020.11.010_bib16","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1182\/blood-2018-99-113360","article-title":"Quality of life in chronic myeloid leukemia patients with deep molecular response who stopped therapy by tyrosine kinase inhibitors: interim results of russian prospective multicenter trial RU-SKI","volume":"132","author":"Petrova","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jval.2020.11.010_bib17","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jval.2020.11.010_bib18","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/cncr.31411","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group","volume":"124","author":"Rea","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2020.11.010_bib19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/bjh.13983","article-title":"How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience","volume":"176","author":"19Ferrero","year":"2017","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.jval.2020.11.010_bib20","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2020.11.010_bib21","series-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"key":"10.1016\/j.jval.2020.11.010_bib22","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","article-title":"Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force","volume":"17","author":"Sullivan","year":"2014","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.11.010_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.jval.2013.02.002","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS)\u2014explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines\u00a0Good Reporting Practices Task Force","volume":"16","author":"Husereau","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.11.010_bib24","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2020.11.010_bib25","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jval.2020.11.010_bib28","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/ejh.12743","article-title":"Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence","volume":"97","author":"Gunnarsson","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jval.2020.11.010_bib30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/0272989X13519863","article-title":"The life table method of half cycle correction: getting it right","volume":"34","author":"Barendregt","year":"2014","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jval.2020.11.010_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0010-4655(91)90191-M","article-title":"An introduction to the method of moments","volume":"68","author":"Newman","year":"1991","journal-title":"Computer Physics Comm"},{"key":"10.1016\/j.jval.2020.11.010_bib33","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1182\/blood.V128.22.1887.1887","article-title":"Second attempt to discontinue TKI in CML patients who have sustained CMR for over 2 years is rarely successful even with the use of second generation TKIs","volume":"128","author":"Matsuki","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jval.2020.11.010_bib34","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib (STIM1) Study in patients with chronic myeloid leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jval.2020.11.010_bib35","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jval.2020.11.010_bib36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.255.255","article-title":"Long-term follow-up after imatinib cessation for patients in deep molecular response: the update results of the STIM1 study","volume":"122","author":"Mahon","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jval.2020.11.010_bib37","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jval.2020.11.010_bib38","first-page":"1","article-title":"Budget impact of treatment-free remission in treating chronic-phase Philadelphia-positive chronic myeloid leukemia in Lebanon","volume":"5","author":"Elias","year":"2019","journal-title":"J\u00a0Glob Oncol"},{"issue":"3","key":"10.1016\/j.jval.2020.11.010_bib39","doi-asserted-by":"crossref","first-page":"e97","DOI":"10.1111\/bjh.16511","article-title":"A\u00a0single center evaluation of cost savings related to treatment-free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco-economy larger study","volume":"189","author":"Etienne","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jval.2020.11.010_bib40","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1111\/cas.14430","article-title":"Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients","volume":"111","author":"Yamazaki","year":"2020","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jval.2020.11.010_bib41","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520345289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301520345289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:22:57Z","timestamp":1761096177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301520345289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1098301520345289"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.11.010","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}